Sangamo dumps Alzheimer's drug in wake of PhII; Ultragenyx wins orphan drug designations;

@FierceBiotech: ICYMI yesterday: Salk heavyweight Evans raising $33M for an intriguing stealth biotech. Article | Follow @FierceBiotech

@JohnCFierce: The next-next gen thing: Merck and Gilead square off in battle of the next-next-gen hep C combos. Report | Follow @JohnCFierce

> Sangamo ($SGMO) says that a Phase II study of CERE-110 was completed for Alzheimer's, allowing it to dump the drug acquired in a buyout of Ceregene. The company's Q1 release states that it had already revealed that they were going to terminate the program once it was completed. In a message to FierceBiotech, Sangamo CEO Edward Lanphier said that "we said back in 2013 when we acquired Ceregene that we did not intend to pursue this program. It is not a ZFP Tx approach." Investigators say the drug was safe and well tolerated. Release

> Regulators handed Ultragenyx two orphan drug designations for triheptanoin (UX007). The FDA came through on fatty acid oxidation disorders, and the European Commission has granted orphan status for the treatment of glucose transporter type-1 deficiency syndrome. The FDA granted orphan drug designation for triheptanoin in Glut1 DS in October 2014. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: WuXi and DNAnexus join up for cloud-based genomic services. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: FDA issues new guidelines on acceptance of data from overseas clinical trials. Story | Follow @VarunSaxena2

@EmilyWFierce: FBI admits to decades of flawed hair analysis. Washington Post story | Follow @EmilyWFierce

> Diabetes device sales bounce back at Abbott with FreeStyle Libre. More

> St. Jude aims for Axium approval before year-end, with robust neuromodulation growth in 2016. Report

Pharma News

@FiercePharma: Dog data at AACR cancer confab may point to personalized treatments. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Chinese API maker Yunnan Hande Bio-Tech gets a second FDA warning letter. Report | Follow @EricPFierce

@CarlyHFierce: Pfizer's Lyrica team matches the spokesman to the message. FiercePharmaMarketing article | Follow @CarlyHFierce

> Novartis unleashes M&A scouts as GSK deal starts to deliver on margins. Story

> Eli Lilly can thank Novartis--and low expectations--for its Q1 earnings beat. Article

CRO News

> BioClinica recruits a new eClinical president amid rapid expansion. Item

> WuXi deepens its genomic ties with latest partnership. More

> India's Biocon eyes an IPO for its in-house CRO. Story

> Sartorius snags U.K. CRO BioOutsource with an eye on biosimilars. More

> PPD reaches into China with a new central lab. Article

Vaccines News

> Mymetics-led consortium scores €8.4M to develop thermostable vaccines. More

> PaxVax expands commercial network for typhoid vaccine. Report

> CSL CFO to lead flu vaccine business after 2016 launch. Item

> Sinovac to trial jabs with potential to disrupt Pfizer, GSK in China. Story

> Potency worries prompt GSK flu vaccine recall. Article

Pharma Manufacturing News

> Study finds essential antibiotics are often in short supply in U.S. Item

> Indicted compounder filled prescriptions with fake patient names Silver Surfer, Coco Puff. Report

> Counterfeit Botox again found in the U.S. More

> Bayer to close vet med plant, lay off 130. Story

> Labeling foul-up involving acetaminophen leads RB to recall 135 lots of Mucinex. Article

Pharma Asia News

> Founder Dilip Shanghvi did not buy Daiichi stake, Sun Pharmaceutical says. Item

> China proposes patent law changes to toughen IP protection. More

> Biocon plans India listing for Syngene in R&D funding move. Report

> South Korea's SillaJen eyes Phase III for immunotherapy oncology candidate. Story

> Japan researchers look to upset apple cart of pharma manufacturing costs. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.